A major new multi-center study published in Respiratory Research (July 2025) demonstrates that 4DMedical’s X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®) can reveal early and subtle forms of small airways disease that are often missed by standard tests like spirometry and CT scans. Researchers from Vanderbilt University, Johns Hopkins,
A new study led by UNSW Sydney researchers demonstrates the feasibility and promise of the innovative XV Scanner™ with XV LVAS®, non-invasive imaging tools developed by 4DMedical, for assessing regional lung function in adults with bronchiectasis caused by Primary Ciliary Dyskinesia (PCD) and other conditions.
A new peer-reviewed study published in Respiratory Research confirms that 4DMedical’s CT Lung Ventilation Analysis Software (CT LVAS) provides results comparable to those of the gold standard PET method, as well as two additional research techniques for assessing regional lung function. The findings demonstrate a strong association and agreement between
A new peer-reviewed study published in Respiratory Research confirms that 4DMedical’s CT Lung Ventilation Analysis Software (CT LVAS) provides results comparable to those of the gold standard PET method, as well as two additional research techniques for assessing regional lung function. The findings demonstrate a strong association and agreement between
As COPD continues to grow as a global health burden—predicted by the World Health Organization (WHO) to become the third leading cause of death by 2030—innovative AI-driven medical imaging technologies are rapidly advancing diagnosis, staging, and treatment. In a recent Radiology Today article, "Breathing Room," writer Beth W. Orenstein explores
This study highlights the potential of using XV, an advanced functional imaging tool, to better understand regional lung function and optimize the therapeutic application of Non-Invasive Positive Pressure Ventilation (NIPPV). These insights could pave the way for improved patient outcomes for individuals with respiratory conditions, by tailoring interventions to improve
4DMedical has won a contract with the United States Department of Defense (DoD) to pilot its CT Ventilation-Perfusion (CT:VQ™) technology to assess lung health in a fixed cohort of active duty personnel. This contract builds on the success of 4DMedical's earlier agreement with the DoD for the deployment of its
4DMedical has received clearance from the U.S. Food and Drug Administration (FDA) for its IQ-UIP™ product, an advanced AI-driven lung diagnostic tool designed to revolutionize the diagnosis of Usual Interstitial Pneumonia (UIP), the hallmark radiological pattern for diagnosing Interstitial Pulmonary Fibrosis (IPF).
4DMedical Limited unveiled its innovative CT:VQ technology at RSNA 2024, offering a revolutionary alternative to traditional Nuclear VQ scans, aiming to enhance diagnostic capabilities in lung health. The new imaging solution eliminates the use of radioactive isotopes, streamlining procedures while improving patient access...
4DMedical has been awarded a contract with US-based Imaging Partners of Orange County (IPOC) to provide computed tomography (CT) scans for lung ventilation (LVAS) and lung density (LDAf) analysis. The contract – the term of which extends through March, 2026 – reflects accelerated progress in the commercialisation of 4DMedical’s lung
